to approaches such as gene therapy are limited. Thus, the search for new therapeutic modalities is more frequently targeted towards intracellular events, particularly the intracellular signalling pathways, which regulate cell function and will frequently involve alterations in gene expression. Although the fine details of specific signalling pathways are complex, the principles involved in transducing a signal from the plasma membrane into a biological effect are remarkably similar (fig 1) . The way forward for the treatment of many diseases may well lie in the modulation of one or more elements in these signalling pathways. Whilst our know- Figure 1 Intracellular signalling pathways-a simplified scheme. CeUs are regulated by a variety of external ligands, which mediate their effects via binding to specific receptors. With the exception of steroid hormones, the receptors are located on the plasma membrane and intracellular events are modified as a result of a signaUing cascade initiated at the plasma membrane. The earliest elements in the cascade are tyrosine kinases or transducer proteins which activate a vaniety of enzymes, generating second messengers. The second messengers then activate a range ofprotein kinases which can directly modify cellular proteins or modulate gene expression by activation of a further series of kinases.
ledge ofthe structure and function ofindividual signalling elements, and their interplay, is incomplete, it should ensure that the most appropriate targets are selected for drug intervention.
In recent years we have seen an explosive growth in our understanding of the complexity of signals received by cells. These signals consist of soluble factors and membrane bound ligands on adjacent cells, which together regulate the cells' response to the environment. The intracellular signalling pathways elicited by receptor-ligand interactions frequently comprise enzyme cascades, the complexity ofwhich is further increased by cross-talk between elements of these pathways. The major challenge for the future will be to understand how these signalling pathways interact to regulate normal physiology and how their disregulation contributes to disease. One signalling element that has been extensively studied and implicated in a wide variety of diseases is the serine/threonine kinase, protein kinase C (PKC). PKC was first described by Nishizuka as a calcium and phospholipid dependent protein kinase, which also required diacylglycerol (DAG) for full enzyme activity.3 A pivotal role for PKC in the regulation of cell proliferation and differentiation was soon recognised, based initially on data showing that many growth and differentiation factors mediated their effects via the stimulation of phosphatidylinositol (PI) turnover. PI breakdown generates DAG and increases intracellular Ca++ concentrations, via production of inositol trisphosphate,4 thus providing the co-factors for PKC activation. The identification of PKC as the major intracellular receptor for the tumour promoting phorbol esters5 has further implicated PKC in the modulation of cell proliferation.
As the interest in PKC has increased, the perception of its involvement in cell regulation has been extended beyond cell proliferation. It 20 The PKC family all depend on PS, but respond differently to these phospholipid metabolites-for example, PKC rj is most effectively activated by cholesterol sulphate23 and PKCs are differentially responsive to lysophosphatidic acid.24 PKC can also be inhibited by certain lipids, notably the products of sphingolipid hydrolysis, but nothing is known of isoenzyme susceptibility to these molecules.
In recent years it has become evident that protein kinases, including PKC, exhibit a pronounced autophosphorylation which is often linked to kinase activation. Detailed studies have revealed that autophosphorylation occurs at serine and threonine residues on both the regulatory and catalytic domains of PKC. Moreover, the various PKC isoenzymes show certain differences in their autophosphorylation sites.20PKC 1II phosphorylates on both serine and threonine residues, PKC ct and 4 exclusively autophosphorylate on serine, while PKC PI autophosphorylates primarily on threonine residues.
DOWNREGULATION
When activated PKCs are translocated to the plasma membrane, they can be proteolysed by the neutral proteases calpains I and II. Calpains cleave PKC in the hinge region and thus produce two distinct fragments: a protein comprising the regulatory domain and a protein containing the kinase domain, which is catalytically active in the absence of any activators. The latter fragment is termed PKM. In several different cell types prolonged treatment with phorbol esters results in depletion of cellular PKC. This is because phorbol esters cannot be metabolised within cells and they produce continuous activation of PKC, which ultimately leads to its proteolysis and downregulation. Whether PKC downregulation is as extensive with physiological activators of PKC remains to be determined. The various PKC isoenzymes exhibit quite extreme differences in their susceptibility to downregulation. Some are relatively resistent to calpain and trypsin mediated downregulation-for example, PKC Ot,25 whilst others are more easily inactivated by proteolysis-for example PKC 13 and y. 25 Further work is necessary to determine the role of proteolytic cleavage in PKC activation, degradation, relocation to cellular compartments, and determination of substrate specificity. breast carcinoma cells.36 Sensitivity to chemotherapeutic agents was restored by treatment of these cells with the PKC inhibitor staurosporine. Furthermore, PKC has been shown to play a role in the pathogenesis of several inborn errors of metabolism. In cystic fibrosis, a disorder of electrolyte transport, the cystic fibrosis gene product is a transmembrane conductance regulator. The efflux of Cl-is defective and is potentiated by PKC.44 A second genetic disorder, type 4 mucolipidosis, also involves PKC but in this disease PKC activity is severely reduced due to inhibition by sphingolipids. Thus, altered PKC is not the primary cause of this disease, but its modulation by metabolites raised in this disorder may be the pathogenic mechanism. 43 The role of PKC in secretion is of relevance to several diseases, including diabetes5455 and inflammatory conditions such as rheumatoid arthritis37 and septic shock. Tumour necrosis factor (TNF) is thought to be the main inflammatory agonist responsible for inducing septic shock and PKC activation is required for the lipopolysaccharide (LPS) stimulated release of TNF from Kupffer cells.7 Finally, the regulation of membrane protein expression and therefore surface cell phenotype is also a process which involves PKC.6 Consequently, cell-cell communication and contact are partially regulated by PKC. One important consequence of this involvement is the regulation of homotypic and heterotypic cell adhesion. The disruption of these processes would have severe implications for many physiological functions including immune surveillance and cell survival within tissues. Disregulation of cell-cell contacts is one primary factor in tumour cell metastasis63 and the involvement of PKC has recently been suggested from studies of the antimetastatic ability of PKC inhibitors. It is probable that the full extent of PKC involvement in pathogenesis has not yet been revealed and only a sample of the vast literature on this subject can be presented in this review. The major diseases that show involvement of PKC are therefore indicated in the table. However, what is likely to be more germane to understanding the precise role of PKC in pathogenesis, and to the rational design of new therapeutic agents, is the identification of the specific isoenzymes of PKC involved in particular disease states.
PKC isoenzymes and disease
As seen in the table, data concerning PKC isoenzymes and disease are still lacking in many cases. Where isoenzyme data are available they are usually based upon a single report or are contradictory, reflecting a need for further precise studies in this area of research. Studies that have simply invoked a role for PKC in a particular disease, including many of those recorded in the table, have involved the measurement of total PKC activity in normal and diseased tissue. This may then have been followed by experiments showing that the disease state could be induced by agents that are known to activate PKC, usually the phorbol ester TPA; or alternatively that the disease phenotype could be abrogated in disease models by broad range PKC inhibitors, such as H7 or staurosporine.6465 To date, the use of such broad range PKC activators or inhibitors for the treatment of disease in humans has been very limited. As stated earlier, phase 1 clinical trials are currently in progress, assessing the anticancer potential of an activator of PKC, bryostatin 1. Yet the potential for regulation of PKC as a therapeutic tool in a wide range of diseases is clearly indicated.585963 Undoubtedly, the present lack of information regarding the precise functions of the PKC isoenzymes, a paucity of agents able to selectively modulate the isoenzymes and concern about widespread and non-specific side effects, have led to caution in the therapeutic use of PKC regulating drugs.
Progress is now being made towards the identification of agents that can selectively activate PKC isoenzymes. Several compounds show selectivity in their ability to activate PKC isoenzymes in vitro, including phorbol ester derivatives,66 bile acids 30 and a marine polyether compound, Bistratene A.6768 Caution is required in the use of these agents, as there is evidence that the specificity of certain of these compounds is not retained in vivo. 69 Examples are now also emerging of agents that show selectivity in their inhibition of PKC isoenzymes. The staurosporine analogs Ro3 18425 and Ro318220 are more effective towards the c-PKCs70 and the compound 13-hydroxy-7-octadecadienoic acid inhibits PKC p.71 It is still too early to predict the impact of these drugs on disease therapy, but their efficacy can only be realised if the isoenzymes primarily influencing specific disease phenotypes are identified.
The availability of PKC isoenzyme specific antisera and full length nucleotide sequences for the isoenzymes has meant that both immunological and molecular biology approaches can now be used to investigate PKC isoenzymes in disease. Both the level of expression of PKC isoenzymes and their activation state can be determined; the latter by assessing either the proportion of PKC associated with cell membranes/cytoskeleton or by measuring the autophosphorylation of individual PKC isoenzymes. Both are correlates ofPKC activation. As shown in the table, progress is being made towards identifying which isoenzymes are altered in disease and in several cases the new data have allowed the authors to propose new pathogenic mechanisms.304355 As it is beyond the scope of this review to discuss the role of specific PKC isoenzymes in all of the diseases listed in the table, we will restrict this final section to a consideration of PKC isoenzymes in neoplasia. The identification of specific PKC isoenzyme involvement in disease is most extensive for cancer, has increased understanding of neoplastic progression and has begun to influence the design of novel anticancer drugs. 58 59 Studies of colorectal cancer have shown that carcinogenesis is a multistep process, with distinct stages of initiation and progression. The various genetic aberrations underlying these stages are now well characterised.72 Dogma has for a long time held that cancer was a disease of hyperproliferation and that the DNA mutations detected in colorectal cancer revealed genes involved in cell growth. It is now clear that apoptosis is an equally important regulator of cell numbers and aberrations of p53, a gene with a key role in the regulation of apoptosis,73 are among the most common mutations detected in human tumours. 57 The modulation of genes involved in apoptosis, or their gene products and targets, offers a new direction for cancer therapy57; however, this should not be pursued to the exclusion of other possibilities. As mentioned at the beginning of this article, cancers such as colorectal cancer have a significant non-genetic component involved in disease progression. PKC is the cellular target for several tumour promoters and therefore its role lies in the promotion of neoplasia rather than its initiation. As such, PKC could clearly be involved in the regulation of proliferation and apoptosis. Furthermore, published data indicate that only certain PKC isoenzymes are involved in regulating these processes.'3 15 The initial use of TPA as an activator of PKC has led to much confusion over the role of PKC in cell proliferation and apoptosis. In some cell lines TPA was shown to be cytostatic,7 whereas in others it was mitogenic.7677 TPA has been reported to prevent apoptosis induced by a variety of factors,'478 whilst other authors showed that TPA induces apoptosis.7980 TPA activates PKC isoenzymes differentially, having no effect on the a-PKCs. In addition, TPA can differentially downregulate PKC isoenzymes. In rat pituitary cells treated with TPA, Kiley has shown that PKC P and PKC £ were completely downregulated, whereas PKC oc was only partially reduced.8' When this is taken into account with the differential tissue expression of PKC isoenzymes, it is not surprising that conflicting data were gained by different laboratories. The conflict is now being resolved and it is becoming clear that certain PKC isoenzymes are frequently associated with proliferation and apoptosis, whilst others are involved in differentiation. In myeloid and erythroid progenitor cells, PKC ot and 6 appear to be crucial for cell differentiation,82"8 whereas PKC 1 is involved in proliferation.8'84 As cell proliferation and cell death are intimately linked,85 it is perhaps not surprising that several laboratories, including our own, have reported the involvement of PKC 1 in apoptosis.158687
The molecular basis for an involvement ofPKC ot and 6 in differentiation is not known, but PKC P1l1 has recently been shown to be a mitotic lamin kinase. 84 Goss et al84 have shown that PKC P131 is one of the kinases involved in the phosphorylation of nuclear lamin B before lamina disassembly and mitosis. Exactly how this isoenzyme could also be involved in apoptosis has yet to be demonstrated. However, the onset of apoptosis is also known to require the disassembly of the nuclear lamina. 88 One possibility is that in proliferating cells the activity/expression of PKC 311 is closely regulated throughout the cell cycle, along with the other mitotic lamin kinases. It may be that prolonged or inappropriate activation of PKC p111 produces prolonged lamina disassembly and aberrant mitosis, leading to apoptosis. Whilst this hypothesis is likely to represent an oversimplified version of the apoptotic process, there are some supporting data. The deoxyphorbol ester 12-deoxyphorbol-1 3-phenylacetate-20-acetate (Doppa) is specific for the activation of PKC 1 in vitro66 and induces apoptosis in promyeloid cell lines. 86 As the in vivo specificity of this agent has been questioned,69 these data must be taken as preliminary evidence only. However, expression of PKC P is also increased as neutrophils become senescent and enter apoptosis89 and PKC P expression also correlates with apoptosis in tonsil epithelial cells.87 Thus, although the involvement of PKC 13 in proliferation and apoptosis is suggested by several lines of evidence, the interplay between these two functions is still unknown. However, this isoenzyme clearly represents a possible target for future therapeutic regimes. Whether this is the only isoenzyme with this function is not known, but it appears unlikely. PKC 13 is expressed in most but not all tissues and we have preliminary evidence that an agent which selectively activates PKC 6 also induces apoptosis in haemopoietic cells.67 It may still be the case that this cellular process can be affected by only a few PKC isoenzymes.
In conclusion, whilst we are still at an early stage in our understanding of the involvement ofPKC isoenzymes in disease, there is evidence that they represent feasible targets for therapeutic modulation. Before this can occur, more information is required about the function of individual PKC isoenzymes and redundancy of PKC isoenzymes in cell regulation.90 A wider range of isoenzyme specific activators and inhibitors also needs to be developed. When each of these objectives are realised, it is possible that another option will be available for drug intervention protocols, suitable for the treatment of a wide range of diseases. 
